

Published in final edited form as:

Sci Signal. ; 1(36): ra3. doi:10.1126/scisignal.1161577.

Phosphoinositide 3-Kinase p110 β activity: Key Role in Metabolism and Mammary Gland Cancer but not Development

Elisa Ciraolo¹, Manuela Iezzi⁴, Romina Marone³, Stefano Marengo¹, Claudia Curcio², Carlotta Costa¹, Ornella Azzolino¹, Cristiano Gonella¹, Cristina Rubinetto¹, Haiyan Wu⁵, Walter Dastrù⁶, Erica L. Martin⁷, Lorenzo Silengo¹, Fiorella Altruda¹, Emilia Turco¹, Letizia Lanzetti⁸, Piero Musiani⁴, Thomas Ruckle⁹, Christian Rommel⁹, Jonathan M. Backer⁵, Guido Forni², Matthias P. Wymann³, and Emilio Hirsch^{1,*}

¹ Molecular Biotechnology Center. Department of Genetics, Biology and Biochemistry. University of Torino. Via Nizza 52. 10126 Torino. Italy ² Molecular Biotechnology Center. Department of Clinical and Biological Sciences, University of Torino. 10126 Torino. Italy ³ Inst. Biochemistry and Genetics, Dept. Biomedicine University of Basel, Mattenstrasse 28. CH-4058 Basel. Switzerland ⁴ Aging Research Centre. G. d'Annunzio University Foundation. Chieti. Italy ⁵ Department of Molecular Pharmacology. Albert Einstein College of Medicine. Bronx, NY. USA ⁶ Department of Chemistry IFM, via P. Giuria, 7. Molecular Imaging Center, via Nizza 52. University of Torino. Torino. Italy ⁷ Department of Anesthesia and Critical Care. University of Torino. Corso Dogliotti 14. 10126 Torino. Italy ⁸ Dipartimento di Scienze Oncologiche. University of Torino. Istituto per la Ricerca e la Cura del Cancro, Str. Provinciale 142, 10060 Candiolo, Torino, Italy ⁹ Merck Serono S.A. Geneva Research Center, Geneva. Switzerland

Abstract

The phosphoinositide 3-kinase (PI3K) pathway crucially controls metabolism and cell growth. Although different PI3K catalytic subunits are known to play distinct roles, the specific in vivo function of p110 β (the product of the *PIK3CB* gene) is not clear. Here, we show that mouse mutants expressing a catalytically inactive *PIK3CB*^{K805R} mutant survived to adulthood but showed growth retardation and developed mild insulin resistance with age. Pharmacological and genetic analyses of p110 β function revealed that p110 β catalytic activity is required for PI3K signaling downstream of heterotrimeric guanine nucleotide-binding (G protein)-coupled receptors as well as to sustain long term insulin signaling. In addition, *PIK3CB*^{K805R} mice were protected in a model of *ERBB2*-driven tumor development. These findings indicate an unexpected role for p110 β catalytic activity in diabetes and cancer, opening potential new avenues for therapeutic intervention.

Introduction

Phosphoinositide 3-kinases (PI3Ks) and their lipid product phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P₃] are involved in signaling events influencing a large number of cellular processes (1–3). Class I_A PI3Ks are mainly activated by receptor tyrosine kinases (RTKs) and form heterodimers composed of a catalytic subunit (p110 α , β , or δ , which are encoded by the *PIK3CA*, *PIK3CB*, and *PIK3CD* genes, respectively) and a SH2 domain-containing adaptor protein (p85 α , p50 α , p55 α , p85 β or p55 γ) (3). Class I_A PI3Ks are activated

#This manuscript has been accepted for publication in Science Signaling. This version has not undergone final editing. Please refer to the complete version of record at <http://www.sciencesignaling.org/>. The manuscript may not be reproduced or used in any manner that does not fall within the fair use provisions of the Copyright Act without the prior, written permission of AAAS.

*To whom correspondence should be addressed; E-mail: E-mail: emilio.hirsch@unito.it.

by either p85 recruitment to phosphorylated RTKs and adaptors like insulin receptor substrate 1 and 2 (IRS-1/2) or by binding to Ras (2). Whereas p110 α is known to play a major role in insulin signaling (4,5), and p110 δ in lymphocyte activation (6), the role of p110 β has remained elusive. Pharmacological studies have suggested a role for p110 β in platelet aggregation (7); however, the early embryonic lethal phenotype caused by its genetic ablation (8) has prevented accurate characterization of its *in vivo* function.

Aberrant regulation of the PI3K signaling pathway is frequently associated with cancer (9). Mutations in the class IA p110 gene *PIK3CA* can be detected in a number of human tumors (10,11). Although mutations in p110 β corresponding to oncogenic p110 α mutations fail to elicit the same oncogenic behavior (12), overexpression of wild-type p110 β induces transformation in cultured cells (13) and various human cancers show increased abundance of p110 β (14). Nonetheless, whether targeting p110 β could be effective in cancer therapy is unknown.

Here, we show that mice expressing a catalytically inactive form of p110 β survive to adulthood and develop a mild insulin resistance with age. Mutant mice were protected in an *in vivo* model of *ERBB2*-driven mammary gland cancer development, identifying p110 β as a promising drug target with tolerable side effects.

Results

Generation of mice expressing a kinase-dead p110 β mutant

A mouse strain was engineered to carry a mutation in the *PIK3CB* gene (Suppl. Fig. 1) in which Lys805 of the p110 β ATP-binding site was replaced with Arg (*PIK3CB*^{K805R} allele), leading to the production of a catalytically inactive form of p110 β (p110 β ^{K805R}). Unexpectedly, homozygous *PIK3CB*^{K805R/K805R} mice were viable and reached adulthood. However, 50% fewer *PIK3CB*^{K805R/K805R} mice were born from heterozygous crosses than expected (50 mutant homozygotes out of 372 mice analyzed; $P < 0.0001$ by χ^2), indicating embryonic lethality with incomplete penetrance. This phenotype could not be associated to expression of aberrant p110 β variants still retaining partial catalytic activity (Suppl. Fig. 2a–e).

Unexpected non-catalytic function of p110 β

At embryonic day 13.5, two distinct groups of *PIK3CB*^{K805R/K805R} littermate embryos were found: approximately 70% appeared normal, whereas approximately 30% were abnormally small and moribund. The existence of these two distinct groups appeared to be related to genetic background because increased contribution of the C57/BL6J background resulted in a marked decrease in the percentage of normal homozygous embryos. In murine embryonic fibroblasts (MEFs) derived from these two mutant populations, the protein and mRNA abundance of p110 β ^{K805R} was different (Fig. 1a, b and Suppl. Fig. 2g); it reached 60 to 80% of control amounts in normal embryos (*PIK3CB*^{K805R/K805R} High) but only 5 to 20% of wild-type p110 β amounts in abnormal embryos (*PIK3CB*^{K805R/K805R} Low). In MEFs from *PIK3CB*^{K805R/K805R} High, enzymatic activity of p110 β ^{K805R} did not increase above background (Fig. 1c and d) however p110 α and p85 expression were not altered from that in wild-type MEFs (Fig. 1a and b). Similarly, both total class IA PI3K activity, precipitated with beads linked to a phosphopeptide that mimicked an activated growth factor receptor (Fig. 1d, Suppl. Fig. 2f), and p110 α activity, immunoprecipitated with antibodies directed against p110 α , (Suppl. Fig. 2f) were normal, showing that the *in vitro* activity of other class IA PI3Ks was unaltered. Further, decreased p110 β abundance did not cause any substantial increase in free p85 (Suppl. Fig. 3).

Lack of p110 β leads to early embryonic lethality associated with defective cell proliferation (8) and, in agreement, impaired cell proliferation was found in *PIK3CB*^{K805R/K805R Low} MEFs. In contrast, *PIK3CB*^{K805R/K805R High} cells unexpectedly proliferated at a rate similar to that of wild-type MEFs (Fig. 1e). Consistent with this, cell proliferation of wild-type MEFs did not change after treatment with the p110 β -selective inhibitors TGX-221 (7) (Fig. 1e) or TGX-155 (15) (Suppl. Fig. 4), suggesting a non-catalytic function of p110 β . p110 β is known to associate with Rab5, a monomeric small guanosine triphosphatase (GTPase) involved in fusion of clathrin-coated vesicles and in growth factor receptor endocytosis (16,17). We thus investigated the possible role of p110 β in these processes. We found that, although the amount of plasma membrane epidermal growth factor receptor (EGFR) was similar in mutant and control cells, internalization of epidermal growth factor (EGF)-activated EGFR in *PIK3CB*^{K805R/K805R Low} cells was impaired compared to both wild-type and *PIK3CB*^{K805R/K805R High} cells (Fig. 2a).

Overexpression of a dominant-active Rab5 mutant (Rab5Q79L) did not rescue EGFR internalization in the *PIK3CB*^{K805R/K805R Low} MEFs (Suppl. Fig. 5), suggesting a role of p110 β at early steps of endocytosis. Consistently, *PIK3CB*^{K805R/K805R Low} MEFs showed a decrease in the numbers of clathrin-positive vesicles beneath the plasma membrane compared to control cells. In contrast, clathrin staining in the perinuclear region was not affected (Fig. 2b). Moreover, recruitment of the Rab5 effector early endosomal antigen 1 (EEA1) to early endosomes was reduced in *PIK3CB*^{K805R/K805R Low} MEFs (Fig. 2b), likely as a consequence of alterations in the endocytic route.

Requirement for p110 β catalytic function downstream of both receptor tyrosine kinases and G protein-coupled receptors

Comparison of wild-type and *PIK3CB*^{K805R/K805R High} MEFs revealed that the catalytic function of p110 β was not required for Akt activation 5 minutes after stimulation with insulin, insulin-like growth factor 1 (IGF-1), EGF, or platelet-derived growth factor (PDGF) (Fig. 3a and Suppl. Fig 6). Nonetheless, p110 β catalytic activity in MEFs was required for lysophosphatidic acid (LPA)- and sphingosine-1-phosphate (S1P)-dependent phosphorylation of Akt (Fig. 3b and 3c), providing genetic evidence for the involvement of p110 β in heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptor (GPCR) signaling, as previously suggested (5,18,19).

Despite the normal growth of *PIK3CB*^{K805R/K805R High} MEFs in culture, *PIK3CB*^{K805R/K805R} mice showed growth retardation, suggesting p110 β involvement in growth control in vivo. *PIK3CB*^{K805R/K805R} mice were born smaller than controls and showed an average 20% growth retardation that was compensated only after 24 weeks of age, at which time they did not show a significant reduction in muscle weight or alteration in fat mass (Fig. 3d and e, and Suppl. Fig. 7a and b). The abundance of p110 β ^{K805R} in various tissues, including liver, fat, and skeletal muscle, appeared lower than in controls but was never as low as in MEFs derived from abnormal embryos (Suppl. Fig. 7c). Mutant livers also displayed normal amounts of insulin receptor- β (IR β) and IRS-1 (Suppl. Fig. 7d). In *PIK3CB*^{K805R/K805R} liver extracts, p110 β enzymatic activity was undetectable; however, PI3K activity precipitated by either anti-p110 α antibodies or pan-p85 unselective antibodies or by phosphopeptide-linked beads (Suppl. Fig. 2f) was unaltered, suggesting normal in vitro activity of other class I α PI3K. *PIK3CB*^{K805R/K805R} mice developed increased blood glucose and signs of mild insulin resistance that was detectable from 6 months of age (Fig. 4a–f). This phenotype was accompanied by pancreatic islet hyperplasia and increased insulin secretion (Fig. 4g). Furthermore, mutant mice showed reduced hepatic glycogen deposits and defective insulin-mediated inhibition of gluconeogenesis (Fig. 4h–j), indicating that the mutation impacts insulin-mediated control of liver metabolism. Similarly, mutant mice showed decreased

expression of sterol regulatory element-binding protein factor 1C (SREBF-1c), a transcription factor that regulates the lipogenic program, as well as reduced serum triglycerides and cholesterol, demonstrating abnormal lipid metabolism in the liver and consequent dyslipidemia (Table I).

Because these findings appear inconsistent with a major role of p110 α in insulin signaling (4, 5), we sought to define the molecular mechanism involved, by analyzing the signaling complex at the activated insulin receptor. In agreement with p110 α being crucial for acute insulin receptor signaling, at early time points after insulin stimulation 8 week-old *PIK3CB*^{K805R/K805R} livers showed normal recruitment of p85 and p110 α to IRS-1 (Fig 5a) as well as unaltered p110 α activity (Suppl. Fig. 7e) and Akt phosphorylation (Fig 5b). However, in livers of wild-type mice treated with TGX-155 or of *PIK3CB*^{K805R/K805R} mice, insulin-evoked Akt activation declined significantly faster than in untreated wild-type controls (Fig. 5b). Similar results were observed in insulin-stimulated HepG2 hepatoma cells treated with TGX-221 (Suppl. Fig. 8).

Requirement for p110 β in ERBB2-mediated mammary carcinogenesis

The observation that p110 β catalytic function was required for insulin signaling suggested that this isoform could also be involved downstream of other growth factor receptors or their oncogenic forms. Because p110 β can be activated downstream of EGFR (17,20) and is homogeneously expressed in the epithelium of mammary ducts (Fig. 6a), we studied the *PIK3CB*^{K805R} mutation in a model of breast cancer triggered by activated *ERBB2* (also known as HER-2 or neu) (21,22), an oncogene known to signal through an unidentified PI3K isoform (s) (23). *PIK3CB*^{K805R/K805R} mice were intercrossed with BalbC transgenic mice expressing activated *ERBB2* (neuT) in the mammary gland. A cohort of 7 *PIK3CB*^{K805R/K805R}/neuT and 10 *PIK3CB*^{WT/WT}/neuT female mice was followed for 350 days. In agreement with whole mount preparations showing a strong reduction of the side buds at 10 weeks of age (Fig. 6c), development of the first tumor was substantially delayed in *PIK3CB*^{K805R/K805R}/neuT mice (Fig. 6b and Table II). Furthermore, at least up to 380 days of life, *PIK3CB*^{K805R/K805R}/neuT mice showed a reduced number of tumors (Suppl. Fig. 9a), which grew at a significantly lower rate than in *PIK3CB*^{WT/WT}/neuT controls (Table II and Suppl. Fig. 9b). Immunohistochemistry showed expression of activated *ERBB2* in both genotypes; however, the foci of transformation and the high numbers of proliferating Proliferating Cell Nuclear Antigen (PCNA)-positive cells, which completely filled duct lumina of *PIK3CB*^{WT/WT}/neuT mammary glands, were reduced in mutant samples, which showed empty and scarcely proliferating structures (Fig. 6d). To determine whether this protection was intrinsic to the function of p110 β in mammary gland epithelium, cells from multiple primary tumors were bulk cultured in vitro.

Immunostaining with antibodies directed against E-Cadherin confirmed that these cultures consisted of a homogeneous epithelial population (Suppl. Fig. 10). *PIK3CB*^{K805R/K805R}/neuT cells showed an average one third reduction in total p110 β abundance but normal amounts of p110 α and p85 (Fig. 7a). The development of tumors in compound-mutant mice correlated with mutations downstream of PI3K because a reduction in the amount of the PtdIns(3,4,5) P₃ phosphatase PTEN was detected in polyclonal *PIK3CB*^{K805R/K805R}/neuT tumors (Fig. 7a). Despite the decrease in PTEN abundance, *PIK3CB*^{K805R/K805R}/neuT cell populations grew significantly slower than controls (Fig. 7b). To test if this effect was due to either the lack of the kinase activity or the reduction in p110 β ^{K805R} expression, cells of both genotypes were cultured in the presence of p110 β -selective inhibitors, TGX-155 or TGX-221 (7,15,24) (Fig. 7b). This treatment did not show effects in *PIK3CB*^{K805R/K805R}/neuT cells but caused a significant reduction in proliferation in wild-type tumor cells, demonstrating that oncogenic *ERBB2* drives tumor growth largely through p110 β catalytic activity.

Discussion

Whereas PI3Ks-mediated signaling has been implicated in the control of cell proliferation, survival, and metabolism, the specific role of the p110 β isoform has long remained elusive. We showed here that, unexpectedly, p110 β possesses both kinase-dependent and independent functions. Indeed, our results indicate that p110 β may have a scaffolding function, as already shown for the G protein-coupled p110 γ (25). The kinase-independent function(s) of p110 β are sufficient for embryonic development because low abundance of p110 β protein led to embryonic lethality and the presence of p110 β --even in a catalytically inactive form--was sufficient to allow embryonic development and viability to adulthood.

The existence of a multiprotein complex containing both p110 β and Rab5 (16,17) suggests a potential function of p110 β in clathrin-mediated endocytosis. Our results are consistent with p110 β being mainly associated with clathrin-coated vesicles (16) and support the requirement for p110 β kinase-independent activity early in the endocytic pathway. Indeed, our findings suggest that GTP-bound active-Rab5 recruits p110 β to clathrin-coated pits or vesicles and that the scaffolding activity of p110 β contributes to their assembly. In the absence of such scaffolding function clathrin-coated vesicles seem to be inefficiently formed. In turn, this appears to affect the Rab5-dependent endocytic pathway resulting in a decrease of EEA1-positive endosomes.

Despite the unexpected finding of its non-catalytic function, p110 β kinase activity is clearly required downstream of both receptor tyrosine kinases and GPCRs. For example, GPCR signaling triggered by S1P and LPA required p110 β to trigger Akt phosphorylation. This provides a simple mechanistic explanation for the apparently paradoxical ability of GPCRs to trigger PI3K signaling in cells not expressing p110 γ , the prototypical GPCR-activated PI3K (26). Our findings are in agreement with recent reports (27,28) and with earlier pioneering studies indicating GPCR-mediated p110 β activation (19) by direct association of p110 β with the $\beta\gamma$ dimer of heterotrimeric G proteins (18).

On the other hand, our data also indicate p110 β catalytic function is required downstream of receptor tyrosine kinases and contributes to insulin receptor signaling. *Pik3cb*^{K805R/K805R} mice show a mild increase in blood glucose and peripheral insulin resistance, which is accompanied by increased insulin secretion and pancreatic islet hyperplasia. This is consistent with a compensation typical of the hyperinsulinemia observed in patients with impaired glucose tolerance (29). In addition, decreased hepatic glycogen deposits and defective insulin-mediated inhibition of gluconeogenesis indicate that the absence of p110 β catalytic activity impacts insulin-mediated control of liver metabolism. Similarly, p110 β is required for lipid metabolism and for the regulation of the lipogenic program as demonstrated by the decreased expression of SREBF-1c as well as reduced serum tryglicerides and cholesterol. These finding were unexpected because p110 α is the main PI3K isoform known to be involved in insulin signaling (4,5). Nonetheless, consistent with our findings, reduced p110 β expression correlates with the incidence of type 2 diabetes associated with low birthweight (30). Although p110 α plays a major role in the insulin signaling pathway, we demonstrate that p110 β activity is essential to sustain a prolonged insulin stimulation. Mechanistically, this effect could perhaps be explained through the auto-inhibition of p110 α , but not of p110 β , following insulin stimulation (31). Although the limited extent of Akt phosphorylation impairment suggests a possible combination of kinase-dependent and independent functions of p110 β in insulin signaling, our data show that the catalytic activity of p110 β supports p110 α function. Therefore, whereas the spike of PI3K signaling following insulin and growth factor stimulation depends on p110 α (5), our results provide conclusive genetic evidence that p110 β supports the PtdIns(3,4,5) P_3 production that sustains this response.

A similar mechanism could account for the reduced tumorigenicity associated with oncogenic *ERBB2* signaling. Previous reports have demonstrated that PI3K signaling is involved in *ERBB2*-mediated proliferation of mammary gland epithelium (32) but have also shown that mutations of the p110 α -encoding *PIK3CA* gene are associated with *ERBB2* amplification, suggesting a link between p110 α and *ERBB2* signaling (33). However, as decreased proliferation is detected in *PIK3CB*^{K805R/K805R}/neuT compound mutant mammary glands, it is possible that, instead of p110 α , p110 β is the critical PI3K involved in *ERBB2*-positive cancer cell proliferation. *PIK3CA* mutation is mutually exclusive with the loss of the PtdIns(3,4,5)₃ phosphatase PTEN (33) suggesting that p110 α might play little role when PTEN is absent. In agreement, prostate cancer development triggered by PTEN loss is blocked by the lack of p110 β and not p110 α (27). Our data confirm and extend this idea, providing the first conclusive evidence that inhibition of the catalytic activity of p110 β reduces proliferation of mammary gland cancer cells even in conditions of low PTEN abundance.

In conclusion, the data presented here indicate that the kinase-independent function(s) of p110 β are sufficient for embryonic development but that p110 β kinase activity is needed for normal insulin receptor signaling and for the growth of *ERBB2*-dependent mammary gland cancers (Fig. 8). These results suggest highly tissue-specific functions for p110 β and indicate that p110 β targeting could represent a promising option for treatment of selected tumors such as *ERBB2*-driven breast cancer.

Materials and methods

Mice

The targeting strategy used to generate the *PIK3CB*^{K805R} allele was similar to that previously used to generate the *PIK3CG*^{K833R} allele (25). Briefly, the point mutation leading to the substitution with an R of the K⁸⁰⁵ crucial for kinase activity was generated by site directed-mutagenesis of the *PIK3CB* cDNA and fused in frame with the *PIK3CB* 5th coding exon, followed by an internal ribosome entry site-enhanced Green Fluorescent Protein (IRES-eGFP) cassette and a pA signal. A Neo^F/HSV thymidine kinase selection cassette flanked by loxP sites was placed upstream of the mutant cDNA. To allow conditional expression of the kinase-dead p110 β mutant, a duplicated *PIK3CB* 5th coding exon fused in frame with the *PIK3CB* wild-type cDNA and flanked by loxP sites was placed upstream of the selection cassette. The construct was electroporated in E14 embryonic stem (ES) cells and two independent recombinant clones were isolated. Heterozygous mice obtained from germ line chimeras were bred with Balancer Cre mice to delete the wild-type cDNA cassette and progeny were intercrossed to obtain *PIK3CB*^{K805R/K805R} mice. Phenotypic analysis was carried out on two lines derived from independent clones. Results were obtained studying wild-type and mutant littermates derived from heterozygous crosses of mixed 50% 129/Sv-C57Bl/6J-50% BalbC genetic background as well as in 9th generation C57Bl/6J (for diabetes studies) and 3rd generation BalbC (for cancer studies) backcrossed mice.

Reagents

The antibody directed against p110 β was from S. Cruz Biotechnology (# sc-602). Antibodies directed against total Akt and P-Ser473 Akt were from a mouse monoclonal clone and from Cell Signaling Technology (#9271), respectively. Antibodies directed against p85 (#4257) and p110 α (#4254) were from Cell Signaling Technology. Antibodies directed against IRS-1 (#05-699) and insulin receptor α subunit (#07-724) were from Upstate.

Protein analysis

Tissues were removed, frozen in liquid nitrogen, and homogenized in lysis buffer (50mM Tris-HCl pH 8 and 150 mM NaCl) supplemented with 2 mg/ml aprotinin, 1 mM pepstatin, 1 ng/ml

leupeptin, 50 mM NaF, 2 mM Sodium O-vanadate, 1 mM sodium pyrophosphate, and 1% Triton X-100. The same buffer was used to solubilize protein extracts from cultured cells. Homogenates were clarified by centrifugation in a microcentrifuge at 4°C. Supernatant were analyzed for immunoblotting or immunoprecipitated for either 1h or overnight with the indicated antibodies. Immunocomplexes were bound to 30 µl of a suspension of 50% protein A- or protein G-Sepharose beads and washed with lysis buffer. Beads were resolved on SDS-PAGE and transferred on PVDF membranes. Blots were probed with the indicated antibodies and developed with enhanced chemiluminescence (ECL, Millipore).

Lipid kinase assay

p110 α , p110 β and pan-p85 were immunoprecipitated using specific antibodies. Alternatively, all class IA PI3K were pulled down with a phosphopeptide YpVPMLG corresponding to the consensus sequence next to Tyr 751 of the human PDGF receptor β . Proteins were then incubated with 10 mg of phosphatidyl inositol and radiolabeled ATP (10 mM cold ATP, 5 µCi P³² ATP). PtdIns(3)P products were resolved by thin-layer chromatography and visualized with autoradiography.

Endocytosis assays

Endocytosis assay was performed as described (34). Briefly, MEF cells were serum-starved for 2 hours in Dulbeccos's Modified Eagle Medium (DMEM) supplemented with 0.3% BSA. Cells were incubated with purified EGF (100 ng/ml Upstate Biotechnology Inc.) or fluorescently labelled EGF in DMEM supplemented with 0.3% BSA at 4 °C for 1 hour. The EGF-containing medium was then replaced with warm DMEM and cells were incubated at 37°C for a further 15 min. Cells were fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.1% TritonX-100 in PBS for 10 min. Cells were extensively washed and stained with monoclonal anti-EGFR antibody (Oncogene Science, USA, catalog n. Ab-1), anti-EEA1 antibody (Santa Cruz, CA, USA, catalog n. SC6415), and anti-clathrin antibody (Affinity Bioreagents, CO, USA, catalog n. MA1-065) followed by Cy3-conjugated goat anti-mouse IgG (1:400 in PBS). Nuclei were stained with DAPI (Sigma). Time point 0 was obtained by fixing the cells after incubation with EGF at 4°C for 1 hour. Cells were stained without permeabilization as described above.

Cell culture and proliferation

For determination of relative growth, MEFs were seeded in triplicate at 2.5×10^5 cells per 6 cm tissue culture dish, with DMEM containing GlutaMAX and 4.5g/l glucose, (Invitrogen, USA) supplemented with 10% Fetal Bovine Serum (FBS). Cell numbers were evaluated using an automatic cell counter (Casy Technology, Germany). For measurement of tumor proliferation, cells were seeded in triplicate at 5×10^3 cells per 96 well dish and counted using an 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based colorimetric assay (Roche, Germany). Inhibitors of p110 β were added to the culture 24 hours after plating. Data are the average of at least three independent experiments.

Metabolic studies

Measurements of body weight and length, glucose tolerance tests, and plasma insulin level determination were performed as previously described (35). Insulin tolerance tests were conducted on randomly fed (fed ad libitum) mice, by intraperitoneal injection of 1 U/kg of recombinant human insulin, followed by measurement of blood glucose at various time points. Plasma insulin was dosed using a RIA kit (#SRI-13K; LINCO Research, USA) following manufacturer's instructions. Measurement of other hematological parameters and quantitative polymerase chain reaction (PCR) were performed following standard protocols (36). Glycogen was measured as described (37).

Histological analysis

For pancreatic islet morphometric analysis, tissue was fixed in 10% neutral-buffered formalin, embedded in paraffin and cut into 5 μm thick sections. Sections were stained with haematoxylin and eosin following standard protocols. Islet area was measured with the Metamorph software in 8 sections 200 μm apart. Nuclei in each islet were counted and normalized to the measured area.

Histology, immunohistochemistry and mammary gland whole mount preparations were performed as previously described (38).

For mammary gland immunofluorescence analysis, mammary glands were fixed in PLP (4% paraformaldehyde, 0.2% periodate, 1.2% lysine in 0.1 M phosphate buffer), embedded in Optimum cutting temperature (OCT) freezing medium and cut into 5 μm thick sections. Fluorescently labeled 5g9 anti-p110 β monoclonal antibody was obtained by coupling the purified Ig with Alexa Fluor® 488 (Pierce Biotechnology # 46403, IL, USA).

Statistical analysis

Statistical significance was calculated with Student's t, one or two-way ANOVA tests followed by Bonferroni's post hoc analysis, or Mantel-Haenszel Log-rank test where appropriate. Values are reported as the mean \pm standard error of the mean.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References and Notes

1. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. *Curr Opin Cell Biol* 2005;17:141–149. [PubMed: 15780590]
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet* 2006;7:606–619. [PubMed: 16847462]
3. Hirsch E, Costa C, Ciraolo E. Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. *J Endocrinol* 2007;194:243–256. [PubMed: 17641274]
4. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. *Nature* 2006;441:366–370. [PubMed: 16625210]
5. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. *Cell* 2006;125:733–747. [PubMed: 16647110]
6. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ, Vanhaesebroeck B. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. *Science* 2002;297:1031–1034. [PubMed: 12130661]
7. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabakaran H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH. PI 3-kinase p110beta: a new target for antithrombotic therapy. *Nat Med* 2005;11:507–514. [PubMed: 15834429]
8. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. *Mamm Genome* 2002;13:169–172. [PubMed: 11919689]
9. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. *Nat Rev Cancer* 2005;5:921–929. [PubMed: 16341083]

10. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. *Proc Natl Acad Sci U S A* 2006;103:1475–1479. [PubMed: 16432179]
11. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc Natl Acad Sci U S A* 2005;102:802–807. [PubMed: 15647370]
12. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc Natl Acad Sci U S A* 2005;102:18443–18448. [PubMed: 16339315]
13. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proc Natl Acad Sci U S A* 2006;103:1289–1294. [PubMed: 16432180]
14. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. *Oncogene* 2000;19:5083–5090. [PubMed: 11042696]
15. Robertson AD, Jackson S, Kenche V, Yaip C, Parbaharan H, Thompson P.
16. Christoforidis S, Miaczynska M, Ashman K, Wilm M, Zhao L, Yip SC, Waterfield MD, Backer JM, Zerial M. Phosphatidylinositol-3-OH kinases are Rab5 effectors. *Nat Cell Biol* 1999;1:249–252. [PubMed: 10559924]
17. Shin HW, Hayashi M, Christoforidis S, Lacas-Gervais S, Hoepfner S, Wenk MR, Modregger J, Uttenweiler-Joseph S, Wilm M, Nystuen A, Frankel WN, Solimena M, De Camilli P, Zerial M. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. *J Cell Biol* 2005;170:607–618. [PubMed: 16103228]
18. Maier U, Babich A, Nurnberg B. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. *J Biol Chem* 1999;274:29311–29317. [PubMed: 10506190]
19. Murga C, Fukuhara S, Gutkind JS. A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. *J Biol Chem* 2000;275:12069–12073. [PubMed: 10766839]
20. Lanzetti L, Palamidessi A, Areces L, Scita G, Di Fiore PP. Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. *Nature* 2004;429:309–314. [PubMed: 15152255]
21. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc Natl Acad Sci U S A* 1992;89:10578–10582. [PubMed: 1359541]
22. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. *J Exp Med* 1998;188:589–596. [PubMed: 9687535]
23. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. *Nat Clin Pract Oncol* 2006;3:269–280. [PubMed: 16683005]
24. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. *Biochem J* 2007;404:449–458. [PubMed: 17362206]
25. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin SD, Silengo L, Altruda F, Wetzker R, Wymann MP, Lembo G, Hirsch E. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. *Cell* 2004;118:375–387. [PubMed: 15294162]
26. Hirsch E, Lembo G, Montrucchio G, Rommel C, Costa C, Barberis L. Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. *Thromb Haemost* 2006;95:29–35. [PubMed: 16543958]
27. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature*. 2008
28. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals

- downstream of G protein-coupled receptors and is functionally redundant with p110gamma. *Proc Natl Acad Sci U S A* 2008;105:8292–8297. [PubMed: 18544649]
29. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. *Annu Rev Physiol* 2006;68:123–158. [PubMed: 16460269]
 30. Ozanne SE, Jensen CB, Tingey KJ, Martin-Gronert MS, Grunnet L, Brons C, Storgaard H, Vaag AA. Decreased protein levels of key insulin signalling molecules in adipose tissue from young men with a low birthweight: potential link to increased risk of diabetes? *Diabetologia* 2006;49:2993–2999. [PubMed: 17063325]
 31. Foukas LC, Beeton CA, Jensen J, Phillips WA, Shepherd PR. Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo. *Mol Cell Biol* 2004;24:966–975. [PubMed: 14729945]
 32. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer* 2005;5:341–354. [PubMed: 15864276]
 33. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005;65:2554–2559. [PubMed: 15805248]
 34. Carbone R, Fre S, Iannolo G, Belleudi F, Mancini P, Pelicci PG, Torrissi MR, Di Fiore PP. eps15 and eps15R are essential components of the endocytic pathway. *Cancer Res* 1997;57:5498–5504. [PubMed: 9407958]
 35. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. *Mol Cell Biol* 2005;25:1596–1607. [PubMed: 15713620]
 36. Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKC λ /zeta. *Cell Metab* 2006;3:343–353. [PubMed: 16679292]
 37. Mora A, Lipina C, Tronche F, Sutherland C, Alessi DR. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. *Biochem J* 2005;385:639–648. [PubMed: 15554902]
 38. Quagliano E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R, Cavallo F. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. *J Clin Invest* 2004;113:709–717. [PubMed: 14991069]
 39. We thank Valentina Spaziani, Laura Virgili and Laura Braccini for technical help; Peter Shepherd for inhibitors; Guido Tarone and Bart Vanhaesebroeck for constructive discussions. This work was supported by a grant from University of Torino (ex 60%), PRIN, Telethon, Italian Association for Cancer Research (AIRC) to E.H. and G.F., the Sixth Framework Programme EUGeneHeart and Fondation Leducq to E.H, NIH GM55692 to J.M.B., the EU FP6 grant BBW 03.0441-3/LSHG-CT-2003–502935 and Swiss Natl. Foundation grant 3100A0–109718 to M.P.W.
www.sciencesignaling.org/cgi/content/full/1/36/ra3/DC1




Fig. 1. Kinase-dependent and independent functions of p110β in wild-type (*PIK3CB*^{WT/WT}) and *PIK3CB*^{K805R/K805R} MEFs. A) *PIK3CB*^{K805R} gene dosage inversely correlates with phenotype severity. MEFs were derived from apparently normal (*PIK3CB*^{K805R/K805R High}) or abnormal (*PIK3CB*^{K805R/K805R Low}) 13.5 days post conception (d.p.c.) *PIK3CB*^{K805R/K805R} embryos. Homogenates of MEFs of the described phenotypes were analyzed by SDS-PAGE and immunoblotted with the indicated antibodies. B) Analysis of p85 association to p110 in MEFs. Protein extracts were immunoprecipitated with anti-pan p85 antibodies and immunoblotted using the indicated antibodies. C) Analysis of p110β catalytic activity. Representative lipid kinase assay with p110β immunoprecipitated from wild-type or *PIK3CB*^{K805R/K805R High} MEFs. D) PI3K activity in *PIK3CB*^{K805R/K805R High} (KR) MEFs relative to that in wild type controls (WT), as measured after pull down with anti-p110β antibodies or with phosphopeptide-bound beads associating with all class IA PI3Ks. Asterisks: $P < 0.001$. E)

Proliferation curve of mutant MEFs with high and low p110 β ^{K805R} expression levels compared to that of wild-type MEFs with or without 100 nM TGX-221 treatment (TGX). Statistical significance: *PIK3CB*^{K805R/K805R Low} cells vs. all other conditions (* $P < 0.05$, ** $P < 0.01$); other pairs of datasets: not significant.






Fig. 2.

Analysis of EGF receptor endocytosis. A) Immunofluorescence of cells of the given genotype incubated with EGF for 1 hour at 4°C (0 min) and then shifted to 37°C for 15 minutes (15 min). Merged images show EGFR in white and 4'-6-Diamidino-2-phenylindole (DAPI) in blue. Exposure times were identical for the different genotypes but longer at 0 min to better show cell surface EGFR. B) Immunofluorescence of cells of the given genotype with anti-clathrin (top) or anti-EEA1 antibodies. Merged images show clathrin or EEA1 in red and DAPI in blue.

**Fig. 3.**

In vitro and in vivo consequences of p110 β kinase-dead expression. A) IGF-1 and insulin-dependent Akt (also known as Protein kinase B, PKB) and extracellular signal regulated kinase 1 and 2 (Erk1/2) phosphorylation in wild-type (WT) and kinase-dead (KR) MEFs derived from normal embryos. Shown is a representative Western blot of eight independent experiments analyzing the response at 5 minutes after stimulation. B) Analysis of Akt phosphorylation after stimulation with LPA. Wild-type (WT) and *PIK3CB*^{K805R/K805R High} MEFs were stimulated with 10 μ M LPA in the absence or presence of 100 nM TGX-221. C) Analysis of Akt phosphorylation 5 minutes after stimulation with S1P of cells of the indicated genotype in the presence or absence of the p110 β inhibitor TGX221. Shown is a representative Western blot of three independent experiments. D) Growth analysis of *PIK3CB*^{K805R/K805R} (KR) mice. The figure shows the external appearance of 6 week-old wild-type (WT) and *PIK3CB*^{K805R/K805R} (KR) mice. E) Weight gain curve of wild-type (WT) and *PIK3CB*^{K805R/K805R} (KR) mice from 3 to 24 weeks after birth (males n=13, females n=22; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).

**Fig. 4.**

Insulin-dependent glucose metabolism in 6-month old wild-type (WT) and *PIK3CB*^{K805R/K805R} mice (KR). Statistical significance: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

A) Blood glucose in random fed mice (n=9 per genotype). B) Insulin concentrations in the serum of random fed mice (n=9 per genotype). C) Blood glucose in fasted mice (wild type, n=9; KR, n=6). D) Glucose tolerance test (n=5 per genotype). E) Insulin tolerance test (n=7 per genotype). F) Insulin concentration in serum of glucose-treated fasted animals. G) Analysis of pancreatic islet size. Left: histological sections of hematoxylin-eosin (H & E) stained pancreata. Center: quantification of islet area (n=4 per genotype). Right: immunofluorescence with antibodies directed against insulin (Ins; red) and against glucagon (Gcn; green). Nuclei were stained with bisbenzimidazole (DNA; blue). Bars represent 100 μm . H) Histology of a

representative liver section of the indicated mice stained with the periodate-Schiff (PAS) stain, recognizing carbohydrates. Measurement of % of PAS positive pixels: WT: 7.3 ± 0.9 ; KR: 2.27 ± 0.4 . I) Glycogen levels in the liver of randomly fed 24 week-old mice (n=7). J) Pyruvate challenge of wild-type (WT) and *PIK3CB*^{K805R/K805R} (KR) mice. A bolus of 2 g/kg was administered intraperitoneally in 24 week-old mice fasted for 16 hours and blood glucose was measured at the indicated time points (n=5).




Fig. 5. Role of p110 β in insulin signaling. A) Insulin-induced recruitment to IRS-1 of p85 and p110 α , determined by IRS-1 immunoprecipitation followed by immunoblot, 5 min after insulin stimulation of livers. B) Phosphorylation of Akt (on Thr308 and Ser473) determined by immunoblot, in livers of mice of the indicated genotype with and without TGX-155 treatment. Lower panel: quantification of Akt phosphorylation on Ser473 (n=5; ** $P < 0.01$).




Fig. 6. p110 β is required for *ERBB2*-driven breast cancer development. A) p110 β expression in mammary gland epithelium. Cryostat sections of mammary glands derived from *PIK3CB*^{K805R/K805R}/neuT (KR/neuT) and *PIK3CB*^{+/+}/neuT (WT) virgin females were stained with the anti-p110 β 5g9 monoclonal antibody directly coupled to Alexa 488 (described in Suppl. Fig. 2d; green) as well as with the nuclear stain propidium iodide (red) and analyzed by confocal microscopy. Bar corresponds to 20 μ m. B) Kinetics of tumor appearance in *PIK3CB*^{WT/WT}/neuT (WT/neuT; black lines; n=10) and *PIK3CB*^{K805R/K805R}/neuT (KR/neuT; red lines; n=7) compound mutant mice ($P=0.01$). C) Whole mount preparations of *PIK3CB*^{WT/WT}/neuT and *PIK3CB*^{K805R/K805R}/neuT mammary glands at 10 weeks. Upper panel: *PIK3CB*^{K805R/K805R}/neuT mammary gland shows a reduction of duct side buds constituted by atypical hyperplastic lesions. Lower panel: magnification of the side buds revealing the empty aspect of *PIK3CB*^{K805R/K805R}/neuT hyperplastic lesions. L: lymph node, mh: atypical mammary hyperplasia. Bar corresponds to 1 mm. D) Histology of mammary glands. Ducts were stained with anti Erbb2 and with anti PCNA antibodies to show transgene expression and proliferating cells, respectively. Bar represents 100 μ m. Arrowheads indicate PCNA-positive cells in the mutant sample.




Fig. 7. p110 β kinase activity is required for *ERBB2*-driven breast cancer cell proliferation. A) Western blot analysis of protein expression in cultured mammary tumors of the two genotypes with the indicated antibodies. B) Proliferation curves, reported as relative increase in the number of cells compared to the initial seeding density, of cultured tumor cells of the two genotypes in the absence or presence of the p110 β selective inhibitors TGX-155 (10 μ M) and TGX-221 (100 nM). Statistical significance: wild-type cells vs. all other conditions (* $P < 0.05$, ** $P < 0.01$); other pairs of datasets: not significant.




Fig. 8. Model of the catalytic and non-catalytic functions of p110 β . The catalytic activity of p110 β is triggered by both RTK and GPCR signaling and cooperates in Akt activation, cancer development and glucose homeostasis (left side). p110 β also functions as a scaffold protein (right inset) required for the organization at the plasma membrane of clathrin coated pits or vesicles, thus controlling RTK endocytosis.

Table 1
Metabolic measurements in *Pik3cb*^{K805R/K805R} Mice

	<i>PIK3CB</i> ^{WT/WT}	<i>PIK3CB</i> ^{K805R/K805R}	<i>P</i> by Student <i>t</i>
Triglycerides (mg/dL)	109±11	71±6	<0.05
Cholesterol (mg/dL)	66±3	45±2	<0.01
Free Fatty Acids (mM)	1.5±0.1	1.4±0.1	NS
AST (UI)	78±16	63±8	NS
ALT (UI)	47±12	37±3	NS
Plasma Albumin (g/dL)	2.3±0.1	2.2±0.1	NS
Leptin (ng/ml)	0.72±0.08	0.69±0.09	NS
Cumulative Food Intake (g food/q BW per 10 days)	0.30±0.02	0.27±0.01	NS
SREBF1C mRNA (% of WT)	100	72±4	<0.01
PCK1 mRNA (% of WT)	100	147±6	<0.01
G6PC mRNA (% of WT)	100	172±1	<0.01
FBP1 mRNA (% of WT)	100	134±7	<0.01

AST (aspartate aminotransferase); ALT (alanine transaminase); SREBF1C (sterol regulator element-binding protein-1c); PCK1 (phosphoenolpyruvate carboxykinase-1); G6PC (glucose-6-phosphatase, catalytic subunit); FBP1 (fructose 1,6-bisphosphatase).

Table II
Autochthonous Carcinogenesis in *Pik3cb*^{K805R/K805R}/neuT Mice

	latency ^a	survival ^b	growth ^c
<i>Pik3cb</i> ^{WT/WT} /neuT (n=39)	174±5	207±17	33±12
<i>Pik3cb</i> ^{K805R/K805R} /neuT (n=35)	227±9	279±14	52±5
	p<0.0001	p=0.0134	p<0.05

^{a,b,c}Time in days; (^a)from the birth and the growth of a 2mm diameter tumor; (^b)from the birth and the growth of a 8mm diameter tumor; (^c)time required for a 2mm diameter tumor to reach a 8mm diameter. Growth from 8 to 10mm diameter was not significantly different (n=5 per genotype; not shown).

Statistical analysis: paired t test